These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38970649)

  • 1. Favorable changes in the eGFR slope after dapagliflozin treatment and its association with the initial dip.
    Kawano R; Haze T; Fujiwara A; Haruna A; Ozawa M; Kobayashi Y; Saka S; Hirawa N; Tamura K
    Clin Exp Nephrol; 2024 Jul; ():. PubMed ID: 38970649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.
    Adamson C; Docherty KF; Heerspink HJL; de Boer RA; Damman K; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Solomon SD; Verma S; Bengtsson O; Langkilde AM; Sjöstrand M; Vaduganathan M; Jhund PS; McMurray JJV
    Circulation; 2022 Aug; 146(6):438-449. PubMed ID: 35442064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus.
    Shibata R; Taguchi K; Kaida Y; Fukami K
    Clin Exp Nephrol; 2023 Jan; 27(1):44-53. PubMed ID: 36114995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function.
    Sada K; Hidaka S; Kashima J; Morita M; Sada K; Shibata H
    J Diabetes Investig; 2022 Aug; 13(8):1330-1338. PubMed ID: 35322583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
    Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
    Kraus BJ; Weir MR; Bakris GL; Mattheus M; Cherney DZI; Sattar N; Heerspink HJL; Ritter I; von Eynatten M; Zinman B; Inzucchi SE; Wanner C; Koitka-Weber A
    Kidney Int; 2021 Mar; 99(3):750-762. PubMed ID: 33181154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abrupt Decline in Estimated Glomerular Filtration Rate after Initiating Sodium-Glucose Cotransporter 2 Inhibitors Predicts Clinical Outcomes: A Systematic Review and Meta-Analysis.
    Chuang MH; Tang YS; Chen JY; Pan HC; Liao HW; Chu WK; Cheng CY; Wu VC; Heung M
    Diabetes Metab J; 2024 Mar; 48(2):242-252. PubMed ID: 38273790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.
    Sugiyama S; Jinnouchi H; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Clin Med Res; 2019 Apr; 11(4):267-274. PubMed ID: 30937117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stabilization of kidney function and reduction in heart failure events with sodium-glucose co-transporter 2 inhibitors: A meta-analysis and meta-regression analysis.
    Keidai Y; Yoshiji S; Hasebe M; Minamino H; Murakami T; Tanaka D; Fujita Y; Inagaki N
    Diabetes Obes Metab; 2023 Sep; 25(9):2505-2513. PubMed ID: 37217461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.
    Jongs N; Chertow GM; Greene T; McMurray JJV; Langkilde AM; Correa-Rotter R; Kashihara N; Rossing P; Sjöström CD; Stefánsson BV; Toto RD; Wheeler DC; Heerspink HJL; ;
    J Am Soc Nephrol; 2022 Nov; 33(11):2094-2107. PubMed ID: 35977807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
    J Am Heart Assoc; 2021 Jun; 10(11):e020237. PubMed ID: 34013739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice.
    Hirai T; Kitada M; Monno I; Oda E; Hayashi Y; Shimada K; Takagaki Y; Ogura Y; Fujii M; Konishi K; Sakurai M; Nakagawa A; Koya D
    J Diabetes Investig; 2021 Sep; 12(9):1577-1585. PubMed ID: 33417741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
    Jhund PS; Solomon SD; Docherty KF; Heerspink HJL; Anand IS; Böhm M; Chopra V; de Boer RA; Desai AS; Ge J; Kitakaze M; Merkley B; O'Meara E; Shou M; Tereshchenko S; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Bengtsson O; Langkilde AM; Sjöstrand M; McMurray JJV
    Circulation; 2021 Jan; 143(4):298-309. PubMed ID: 33040613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early reduction in albuminuria is associated with a steeper 'dip' in initial estimated glomerular filtration rate but favourable long-term kidney outcomes in people with diabetes receiving sodium-glucose cotransporter-2 inhibitors.
    Kao YW; Yen KC; Chen SW; Chao TF; Chan YH
    Diabetes Obes Metab; 2024 Jul; ():. PubMed ID: 38951860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteinuria-lowering effects of dapagliflozin are associated with an initial decline in estimated glomerular filtration rate in patients with chronic kidney disease.
    Murakoshi M; Kobayashi T; Kihara M; Ueda S; Suzuki Y; Gohda T
    Nephrology (Carlton); 2023 Oct; 28(10):540-547. PubMed ID: 37357381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.
    Han E; Kim A; Lee SJ; Kim JY; Kim JH; Lee WJ; Lee BW
    Diabetes Ther; 2018 Aug; 9(4):1689-1701. PubMed ID: 29998370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction.
    Miñana G; de la Espriella R; Palau P; Amiguet M; Seller J; García Pinilla JM; Núñez E; Górriz JL; Valle A; Sanchis J; Bayés-Genís A; Núñez J;
    Rev Esp Cardiol (Engl Ed); 2023 Oct; 76(10):783-792. PubMed ID: 36958534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.